Marietta, Ga.-based biopharmaceutical company MiMedx has appointed Timothy Wright as its new CEO.
Three takeaways:
1. MiMedx develops regenerative and therapeutic biologics utilizing human placental tissue allografts. It is primarily involved in advanced wound care, spine and sports medicine.
2. Mr. Wright has over 30 years of experience in the pharmaceutical, biotech and medical devices industries and will begin his role on May 13, succeeding interim CEO David Coles.
3. Mr. Wright's prior experience includes serving as president and CEO of Tampa, Fla.-based biotech company M2Gen Corp. and executive vice president, mergers and acquisitions, strategy and innovation at Israeli multinational pharmaceutical company, Teva Pharmaceutical Industries.